Home LiteratureArticle Details
PMID: 15173875 Published · ppublish English Journal Article Review

Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

The Journal of clinical investigation ·Vol. 113 ·No. 11 ·2004-06-00 ·Pages 1515-25

Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC

Abstract

In recent years, great strides in understanding and regulating the immune system have led to new hope for harnessing its exquisite specificity to destroy cancer cells without affecting normal tissues. This review examines the fundamental immunologic advances and the novel vaccine strategies arising from these advances, as well as the early clinical trials studying new approaches to treat or prevent cancer.

MeSH Terms
Antigens, Neoplasm/immunology Cancer Vaccines/immunology,pharmacology Genetic Vectors Humans Immunotherapy Neoplasms/immunology,prevention & control Vaccines, DNA/immunology,pharmacology Vaccines, Subunit/immunology Viruses
Chemicals
Antigens, Neoplasm Cancer Vaccines Vaccines, DNA Vaccines, Subunit
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Berzofsky Jay A
Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA. [email protected]
Terabe Masaki
Oh SangKon
Belyakov Igor M
Ahlers Jeffrey D
Janik John E
Morris John C
References (123)
123 references, click to expand
  1. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.
    J Immunol. 1999 Jan 15;162(2):989-94 PMID: 9916724
  2. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma.
    J Urol. 2002 May;167(5):1995-2000 PMID: 11956426
  3. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.
    Clin Cancer Res. 2002 Sep;8(9):2782-7 PMID: 12231517
  4. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.
    Biol Blood Marrow Transplant. 2000;6(6):621-7 PMID: 11128812
  5. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.
    J Exp Med. 1996 Jan 1;183(1):317-22 PMID: 8551239
  6. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific.
    J Immunol. 2000 Jan 1;164(1):183-90 PMID: 10605010
  7. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.
    J Exp Med. 1992 Nov 1;176(5):1453-7 PMID: 1402688
  8. CD40 ligation and phagocytosis differently affect the differentiation of monocytes into dendritic cells.
    J Leukoc Biol. 2002 Dec;72(6):1180-9 PMID: 12488500
  9. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.
    Clin Cancer Res. 2002 May;8(5):967-72 PMID: 12006508
  10. Molecular basis of T cell inactivation by CTLA-4.
    Science. 1998 Dec 18;282(5397):2263-6 PMID: 9856951
  11. Immunoregulatory T cells in tumor immunity.
    Curr Opin Immunol. 2004 Apr;16(2):157-62 PMID: 15023407
  12. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?
    J Natl Cancer Inst. 2002 Jun 5;94(11):805-18 PMID: 12048268
  13. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts.
    Int J Cancer. 1997 Mar 17;70(6):706-15 PMID: 9096653
  14. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
    Cancer Res. 2001 Sep 1;61(17):6451-8 PMID: 11522640
  15. Selective induction of high avidity CTL by altering the balance of signals from APC.
    J Immunol. 2003 Mar 1;170(5):2523-30 PMID: 12594278
  16. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.
    J Exp Med. 2003 Dec 1;198(11):1741-52 PMID: 14657224
  17. High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection.
    J Clin Invest. 2001 Dec;108(11):1677-85 PMID: 11733563
  18. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
    Cancer Res. 1999 Oct 15;59(20):5160-8 PMID: 10537292
  19. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes.
    Nature. 2003 Feb 20;421(6925):852-6 PMID: 12594515
  20. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.
    Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13141-6 PMID: 9789055
  21. CTLA-4: new insights into its biological function and use in tumor immunotherapy.
    Nat Immunol. 2002 Jul;3(7):611-8 PMID: 12087419
  22. Human tumor antigens are ready to fly.
    Adv Immunol. 1996;62:217-56 PMID: 8781270
  23. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent.
    J Immunol. 2002 Nov 15;169(10):5796-804 PMID: 12421960
  24. Requirement for CD4 T cell help in generating functional CD8 T cell memory.
    Science. 2003 Apr 11;300(5617):337-9 PMID: 12690201
  25. Dendritic cells in cancer immunotherapy.
    Annu Rev Immunol. 2000;18:245-73 PMID: 10837059
  26. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity.
    Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3392-7 PMID: 12626740
  27. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
    Blood. 1999 Apr 1;93(7):2411-9 PMID: 10090953
  28. Oncogenic proteins as tumor antigens.
    Curr Opin Immunol. 1996 Oct;8(5):637-42 PMID: 8902388
  29. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells.
    Nature. 1992 Nov 19;360(6401):258-61 PMID: 1279441
  30. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.
    Oncogene. 1990 Oct;5(10):1603-10 PMID: 1979160
  31. Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells.
    Mol Ther. 2003 Apr;7(4):498-505 PMID: 12727113
  32. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy.
    Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8809-14 PMID: 11427731
  33. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines.
    Int J Cancer. 1999 Oct 29;83(3):326-34 PMID: 10495424
  34. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity.
    Nat Rev Immunol. 2003 Mar;3(3):211-22 PMID: 12658269
  35. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors.
    J Exp Med. 1997 Oct 6;186(7):1177-82 PMID: 9314567
  36. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.
    J Immunol. 1999 Feb 15;162(4):2227-34 PMID: 9973498
  37. Dendritic cell vaccination for cancer therapy.
    Oncogene. 2000 Dec 27;19(56):6673-9 PMID: 11426654
  38. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy.
    J Immunol. 2001 Dec 15;167(12):7150-6 PMID: 11739538
  39. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.
    J Exp Med. 1999 Dec 6;190(11):1669-78 PMID: 10587357
  40. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells.
    Nat Med. 1996 Jan;2(1):52-8 PMID: 8564842
  41. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.
    J Exp Med. 1995 Jul 1;182(1):255-60 PMID: 7540653
  42. MHC ligands and peptide motifs: first listing.
    Immunogenetics. 1995;41(4):178-228 PMID: 7890324
  43. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma.
    Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2879-83 PMID: 8610135
  44. Genetic immunization is a simple method for eliciting an immune response.
    Nature. 1992 Mar 12;356(6365):152-4 PMID: 1545867
  45. Antigenic peptide binding by class I and class II histocompatibility proteins.
    Structure. 1994 Apr 15;2(4):245-51 PMID: 8087551
  46. Molecular alterations in pediatric sarcomas: potential targets for immunotherapy.
    Sarcoma. 1998;2(2):77-87 PMID: 18521238
  47. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.
    Cancer Res. 2003 May 1;63(9):2127-33 PMID: 12727829
  48. Epitope selection and design of synthetic vaccines. Molecular approaches to enhancing immunogenicity and cross-reactivity of engineered vaccines.
    Ann N Y Acad Sci. 1993 Aug 12;690:256-64 PMID: 7690214
  49. The use of dendritic cells in cancer immunotherapy.
    Curr Opin Immunol. 2003 Apr;15(2):138-47 PMID: 12633662
  50. Molecular mechanisms and biological significance of CTL avidity.
    Curr HIV Res. 2003 Jul;1(3):287-94 PMID: 15046253
  51. Dendritic cell-based vaccination in solid cancer.
    J Clin Oncol. 2003 Jan 1;21(1):135-42 PMID: 12506182
  52. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
    Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43 PMID: 8097319
  53. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides.
    Immunity. 1994 Dec;1(9):751-61 PMID: 7895164
  54. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Cancer Res. 2002 Oct 15;62(20):5845-52 PMID: 12384547
  55. Ins and outs of clinical trials with peptide-based vaccines.
    Front Biosci. 2002 May 1;7:e204-13 PMID: 11991853
  56. A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy.
    Cancer Res. 1999 Jan 15;59(2):301-6 PMID: 9927036
  57. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.
    J Exp Med. 1994 Apr 1;179(4):1109-18 PMID: 8145033
  58. Defective CD8 T cell memory following acute infection without CD4 T cell help.
    Science. 2003 Apr 11;300(5617):339-42 PMID: 12690202
  59. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.
    Nat Med. 1998 Mar;4(3):321-7 PMID: 9500606
  60. Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide.
    J Exp Med. 1994 Feb 1;179(2):473-9 PMID: 8294861
  61. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells.
    J Exp Med. 2001 Jan 15;193(2):233-8 PMID: 11208863
  62. Heterologous protection against influenza by injection of DNA encoding a viral protein.
    Science. 1993 Mar 19;259(5102):1745-9 PMID: 8456302
  63. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
    J Immunol. 1999 Nov 15;163(10):5211-8 PMID: 10553041
  64. Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines.
    Gene Ther. 2000 Dec;7(24):2113-21 PMID: 11223993
  65. Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells.
    Cancer Immunol Immunother. 2002 Mar;51(1):9-14 PMID: 11845255
  66. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease.
    Blood. 1998 Apr 15;91(8):2925-34 PMID: 9531603
  67. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.
    J Natl Cancer Inst. 1997 Feb 19;89(4):293-300 PMID: 9048833
  68. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.
    Immunol Rev. 2002 Oct;188:177-82 PMID: 12445291
  69. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.
    J Clin Oncol. 2003 Apr 15;21(8):1562-73 PMID: 12697882
  70. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans.
    Blood. 2002 Jul 1;100(1):174-7 PMID: 12070024
  71. Immunity to the alpha(1,3)galactosyl epitope provides protection in mice challenged with colon cancer cells expressing alpha(1,3)galactosyl-transferase: a novel suicide gene for cancer gene therapy.
    Cancer Res. 2003 Mar 1;63(5):987-93 PMID: 12615713
  72. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination.
    Hum Gene Ther. 1997 Jul 20;8(11):1355-63 PMID: 9295130
  73. ras oncogenes in human cancer: a review.
    Cancer Res. 1989 Sep 1;49(17):4682-9 PMID: 2547513
  74. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity.
    Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4512-7 PMID: 10200293
  75. T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery.
    J Immunol. 2000 May 1;164(9):4961-7 PMID: 10779807
  76. Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy.
    Clin Orthop Relat Res. 2000 Apr;(373):25-31 PMID: 10810459
  77. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
    Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 PMID: 12826605
  78. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
    Cancer Res. 1997 Oct 15;57(20):4570-7 PMID: 9377571
  79. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines.
    J Exp Med. 1996 Apr 1;183(4):1357-65 PMID: 8666894
  80. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma.
    J Clin Oncol. 2001 Sep 15;19(18):3836-47 PMID: 11559721
  81. Efficient transduction of dendritic cells and induction of a T-cell response by third-generation lentivectors.
    Hum Gene Ther. 2002 Jun 10;13(9):1091-100 PMID: 12067442
  82. Cancer vaccines: progress reveals new complexities.
    J Clin Invest. 2002 Aug;110(3):289-94 PMID: 12163445
  83. The unconventional lifestyle of NKT cells.
    Nat Rev Immunol. 2002 Aug;2(8):557-68 PMID: 12154375
  84. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.
    Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4102-7 PMID: 8633023
  85. A listing of human tumor antigens recognized by T cells.
    Cancer Immunol Immunother. 2001 Mar;50(1):3-15 PMID: 11315507
  86. The biochemistry and cell biology of antigen processing and presentation.
    Annu Rev Immunol. 1993;11:403-50 PMID: 8476568
  87. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations.
    Cancer Res. 2001 Sep 15;61(18):6868-75 PMID: 11559563
  88. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.
    J Clin Oncol. 2000 Dec 1;18(23):3964-73 PMID: 11099326
  89. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity.
    Nat Med. 1995 Dec;1(12):1297-302 PMID: 7489412
  90. Use of intrinsic and extrinsic helper epitopes for in vivo induction of anti-hepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope peptide vaccines.
    J Infect Dis. 1996 Jan;173(1):24-31 PMID: 8537666
  91. Immunotherapy: past, present and future.
    Nat Med. 2003 Mar;9(3):269-77 PMID: 12612576
  92. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
    J Exp Med. 2001 Sep 17;194(6):823-32 PMID: 11560997
  93. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells.
    J Exp Med. 2000 Nov 6;192(9):1213-22 PMID: 11067871
  94. The central role of CD4(+) T cells in the antitumor immune response.
    J Exp Med. 1998 Dec 21;188(12):2357-68 PMID: 9858522
  95. Dendritic cells and the control of immunity.
    Nature. 1998 Mar 19;392(6673):245-52 PMID: 9521319
  96. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.
    Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10067-71 PMID: 9707601
  97. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine.
    Clin Cancer Res. 2000 Jan;6(1):24-33 PMID: 10656428
  98. A triad of costimulatory molecules synergize to amplify T-cell activation.
    Cancer Res. 1999 Nov 15;59(22):5800-7 PMID: 10582702
  99. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma.
    J Clin Oncol. 2003 Feb 15;21(4):624-30 PMID: 12586798
  100. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
    J Exp Med. 2002 Dec 16;196(12):1627-38 PMID: 12486105
  101. T cell fitness determined by signal strength.
    Nat Immunol. 2003 Apr;4(4):355-60 PMID: 12640450
  102. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
    Blood. 2002 Mar 1;99(5):1517-26 PMID: 11861263
  103. Dendritic cell-based treatment of cancer: closing in on a cellular therapy.
    Cancer J. 2001 Nov-Dec;7 Suppl 2:S53-61 PMID: 11777265
  104. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells.
    Int J Cancer. 2000 May 1;86(3):385-92 PMID: 10760827
  105. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
    Blood. 2000 Mar 1;95(5):1781-7 PMID: 10688838
  106. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.
    Nat Med. 1996 Oct;2(10):1096-103 PMID: 8837607
  107. Targeting p53 as a general tumor antigen.
    Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):11993-7 PMID: 8618830
  108. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors.
    Cell Immunol. 1996 May 25;170(1):111-9 PMID: 8665591
  109. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
    Cancer. 2003 Jan 1;97(1):186-200 PMID: 12491520
  110. Human tumor antigens for cancer vaccine development.
    Immunol Rev. 1999 Aug;170:85-100 PMID: 10566144
  111. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
    J Exp Med. 1996 Jan 1;183(1):87-97 PMID: 8551248
  112. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation.
    J Clin Oncol. 2001 Jan 1;19(1):145-56 PMID: 11134207
  113. Active immunization against cancer with dendritic cells: the near future.
    Int J Cancer. 2001 Nov15;94(4):459-73 PMID: 11745430
  114. Inducing long-term survival with lasting anti-tumor immunity in treating B cell lymphoma by a combined dendritic cell-based and hydrodynamic plasmid-encoding IL-12 gene therapy.
    Int Immunol. 2003 Mar;15(3):427-35 PMID: 12618487
  115. Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction.
    Annu Rev Immunol. 1992;10:333-58 PMID: 1590990
  116. Strategies for designing and optimizing new generation vaccines.
    Nat Rev Immunol. 2001 Dec;1(3):209-19 PMID: 11905830
  117. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation.
    Lancet. 1995 Nov 25;346(8987):1399-400 PMID: 7475823
  118. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway.
    Nat Immunol. 2000 Dec;1(6):515-20 PMID: 11101874
  119. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage.
    J Immunol. 1999 Jan 1;162(1):168-75 PMID: 9886383
  120. A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L.
    Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13020-5 PMID: 12232042
  121. Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular antigen processing.
    Int Immunol. 1997 Aug;9(8):1085-93 PMID: 9263005
  122. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells.
    Cancer Res. 1993 Jul 15;53(14):3257-61 PMID: 7686815
  123. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.
    Nat Med. 1998 Mar;4(3):328-32 PMID: 9500607
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
DOI
10.1172/JCI21926
Email
[email protected]
Published
2004-06-00
Pages
1515-25
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC419494
Subset
IM
External Links
PubMed source DOI: 10.1172/JCI21926 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2